Prof. Johann De Bono, MD, PhD

Prof. Johann De Bono, MD, PhD

Professor of Experimental Cancer Medicine
Honorary Consultant Medical Oncologist 
Royal Marsden Hospital
Head of the Division of Clinical Studies
Institute of Cancer Research
London, UK

Related Videos

Given the heterogeneity of genomic aberrations for prostate cancer, what are the limitations of PCR-based "hot spot" panels for identifying actionable molecular profiles, homozygous deletions and other aberrations? Video

Given the heterogeneity of genomic aberrations for prostate cancer, what are the limitations of PCR-based "hot spot" panels for identifying actionable molecular profiles, homozygous deletions and other aberrations?

Given the heterogeneity of genomic aberrations you have described for prostate cancer, what are the limitations of so-called targeted, PCR-based “hot spot” panels for identifying actionable molecular profiles, homozygous deletions and ...

Can you review for us the implications of your study on PTEN genomic rearrangements and loss in prostate cancer and the implications for NGS-based profiling in this disease? Video

Can you review for us the implications of your study on PTEN genomic rearrangements and loss in prostate cancer and the implications for NGS-based profiling in this disease?

Can you review for us the implications of your study on PTEN genomic rearrangements and loss in prostate cancer and the implications for NGS-based profiling in this disease?

How does systematic profiling with NGS optimize genomic and molecular stratification for prostate cancer, and what actionable subgroups and aberrations have you identified? Video

How does systematic profiling with NGS optimize genomic and molecular stratification for prostate cancer, and what actionable subgroups and aberrations have you identified?

In what way does systematic profiling with NGS optimize genomic and molecular stratification for prostate cancer, and what actionable subgroups and aberrations have you identified based on comprehensive genomic assessment?

How is NGS, identification of microsatellite instability and mismatch repair defects, and molecular target stratification that comprehensive genomic profiling improving management of prostate cancer? Video

How is NGS, identification of microsatellite instability and mismatch repair defects, and molecular target stratification that comprehensive genomic profiling improving management of prostate cancer?

How is NGS, identification of microsatellite instability and mismatch repair defects, and molecular target stratification that comprehensive genomic profiling improving management of prostate cancer?